Summit addresses need for innovation

Share this article:
Pharmaceutical e-marketing experts called for more innovation in online efforts as the Web enters its second and third incarnations.

“We need to add what is changing to our planning process,” said Paul Ivans, president, Evolution Road Consulting, at IIR's 6th annual ePharma Summit in Philadelphia. “Strategic and tactical planning must include innovation,” he added.

Ivans was among a number of online experts to address 250 e-marketers at the event. Topics of discussion included the rise of the empowered consumer, growth of user-generated content and ways to drive ROI.

 The event featured a thought leader panel discussion including e-marketers from Genentech, Novartis, Lilly and Wyeth.

“A great Web site user experience will result in the holy grail of better patient outcomes and high ROI,” said Frank Visconti, associate director, marketing, at Novartis Pharmaceuticals.

Ben Lei, senior manager, e-marketing at Genentech said that information needs to be easier for consumers to find.

“We need to remove the clutter,” Lei said.

Amy Chafin, specialty therapeutic area marketing manager at Lilly, said her firm is working on finding the right mix through an integration of “sales force, e-detailing, mobile technology and word-of-mouth marketing.”

Share this article:
close

Next Article in News

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.